Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.

Background And Purpose: For locoregionally advanced HNSCC, chemoradiotherapy with cisplatin or another platinum compound is considered as one of the standard treatment regimes. Cisplatin has improved the loco-regional control, but also increased especially the acute side effects. Cetuximab blocks ligand binding and receptor activation by binding to the extracellular domain of the EGFR.

Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma.

Chemotherapy and/or radiotherapy are established measures in treatment protocols of head and neck squamous cell carcinoma (HNSCC). However, we still lack reliable predictive markers for the response to radio- and chemotherapy. The p53 pathway is involved in stress response and thus might influence chemo-/radiosensitivity.

Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro.

Background And Purpose: The study was performed to measure the radiosensitizing effect of vinorelbine together with gefitinib in head and neck squamous cell carcinoma (HNSCC) cell lines in vitro.

Materials And Methods: Three recently established HNSCC cell lines, originating from larynx and oral cavity tumors, were tested in this study. Vinorelbine concentration of 0.

Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

Purpose: Squamous cell carcinoma of the head and neck (HNSCC) remains a clinical challenge because of the high rate of locoregional disease recurrence. Standard treatment includes surgery, radiation, chemoradiation or a combination of these approaches. New therapies are needed to achieve improved survival, quality of life and organ function in these patients.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Purpose: The epidermal growth factor receptor (EGFR) inhibitor gefitinib (Iressa) has shown antitumor activity in clinical trials against cancers, such as non-small cell lung cancer and head and neck squamous cell carcinoma (HNSCC). Research on non-small cell lung cancer has elucidated factors that may predict response to gefitinib. Less is known about molecular markers that may predict response to gefitinib in HNSCC patients.

Head and neck carcinoma cell lines are sensitive to vinflunine in vitro.

Background: New treatment models are needed for the management of advanced stage head and neck carcinomas (HNSCC). Vinflunine is a novel vinca alkaloid which has shown remarkable improvement in efficiency and reduced side-effects in both in vitro and in vivo studies. Better locoregional control and prevention of distant metastasis in advanced HNSCC would be welcome and, with this new efficient compound, these might be expected.

Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro.

Concomitant chemoradiotherapy has been used for locally advanced head and neck squamous cell carcinoma (HNSCC) particularily with cisplatin, 5-FU, methotrexate, bleomycin and taxanes. Vinorelbine is a semisynthetic vinca alcaloid, which causes a block in the G2/M phase of the cell cycle. HNSCC cell lines have previously been reported to be sensitive to vinorelbine in nanomolar concentrations.

Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in Vitro.

The vinorelbine sensitivity of eight recently established head and neck squamous cell carcinoma (SCC) cell lines was tested using the 96-well plate clonogenic assay. The chemosensitivity of these head and neck SCC cell lines to vinorelbine expressed as IC50, corresponding to the drug concentration causing 50% inhibition in clonogenic survival, varied between 0.6 and 1.